.jpg)
Project Name: UMBRA
Start Date: 3/3/1984
Completion Date: --
Overview: Anti-mutagenic biological immunization.
Note [6/22/18] S. Morrison: With work on Gemini complete, the Director has made a sudden decision to transfer me to the staff of Doctor Bao-Wei Cong and Shengjiao Wu. I will admit some measure of apprehension working for a frozen corpse, but I profess no end to my curiosity at his successes with genetic engineering. The new assignment, to develop a formerly-mothballed anti-mutagenic biological immunization is fascinating. I should have more details in a week's time.
Note [6/29/18] S. Morrison: Apparently this was, and has always been, my project. The Director informed me that in the mid 1980s I was a part of a development of Project Umbra which remained incomplete and that my memories of these events were summarily erased. Given my familiarity with Maury Parkman and Arthur Petrelli, this doesn't seem the least bit surprising. Regretfully, the Director has informed me that there is no way to restore my memories of the research, and that we will be starting anew from scratch.
Note [7/3/18] S. Morrison: We have developed a mission statement: Project Umbra will immunize inoculated subjects against a specific genetic mutation vector communicated through rapid epigenetic manipulation. By preventing communication between heritable phenotypes and DNA methylation we will provide complete immunity to treated subjects.
Note [7/12/18] S. Morrison: I'm not sure to what extent, but I believe we're being kept in the dark on the true nature of this research. The blood samples the Director have been sending us are all from the same individual, an SLC-Expressive with a form of self-sustaining rapid cell regeneration. Doctor Wu believes the key to our research will be contained with mitochondrial DNA information, which I'm not entirely clear on how it relates to Cong's supposition that histone modifications are somehow involved.
Note [7/21/18] S. Morrison: We've hit a brick wall. There's simple not enough information to go on to continue this development. The Director is furious. We're working as best as we can but we're feeling around blind and in the dark. He send us a second DNA sample, this time from a SLC-Expressive woman. Clear evidence of genetic manipulation similar to the Gemini process but operating through a more elegant and complex delivery system. If Gemini is a hammer, this is a scalpel. But we're not being given any technical specifications. Dr. Cong suspects this may not be technologically-derived at all, but immunization against an Expressive ability. Still, that's not an answer.
Note [9/30/18] S. Morrison: Still nothing to report. The Director has been busy and we've been preoccupied trying to scale back the deleterious effects of Gemini's final process on host genes. Not looking good long-term for anyone. Not going to tell Chen that, though.
Note [3/22/19] S. Morrison: Dusting this off, we've received a possible candidate. The kid was a charred corpse when we received him, but the Director was able to perform a full blood transfusion that somehow brought him back to life with some work on our part to cycle the blood through his dead tissue. There wasn't enough to bring back fully, so we ran him through the Hydra process and filled in gaps in new brain tissue with Heisenberg transference. The Director has moved one recipient to a mobile laboratory, the other is remaining here in Praxia to do with as we please. Coding as DC02. Doctor Cong has tagged him for Gemini, his ability would be more useful on someone else at this rate. Blood work is interesting though, his mitochondria appears to have been mutated at some point similar to the Director's, but with variations.
Note [3/28/19] S. Morrison: Initial tests indicate that Subject DC02 is a strong candidate for receipt of Gemini. Cellular breakdown in a lab environment is minimal and on par with Lanhua Chen and the other girls from Dr. Wu's Garden project. Curiously, DC02 shows the same baseline mitochondrial mutations as the Director, but also Chen and the other clones. Beginning to see a pattern here. Just not sure what it is.
Note [5/25/19] S. Morrison: We're still only making minimal headway on Umbra. We've proposed a few different possibilities but none are within acceptable parameters of success. I'm beginning to think that without the original test subjects from the Company's first run we won't be able to accomplish anything.
RECOVERED ATTACHMENTS:
